Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Free Cash Flow (2016 - 2025)

Corcept Therapeutics' Free Cash Flow history spans 10 years, with the latest figure at $38.4 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 35.94% year-over-year to $38.4 million; the TTM value through Dec 2025 reached $141.8 million, down 27.71%, while the annual FY2025 figure was $141.8 million, 27.71% down from the prior year.
  • Free Cash Flow for Q4 2025 was $38.4 million at Corcept Therapeutics, down from $54.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $71.7 million in Q3 2024 and bottomed at $5.0 million in Q1 2025.
  • The 5-year median for Free Cash Flow is $39.6 million (2024), against an average of $37.6 million.
  • The largest annual shift saw Free Cash Flow crashed 83.42% in 2023 before it soared 984.05% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $49.4 million in 2021, then crashed by 32.42% to $33.4 million in 2022, then plummeted by 83.42% to $5.5 million in 2023, then skyrocketed by 984.05% to $59.9 million in 2024, then crashed by 35.94% to $38.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Free Cash Flow are $38.4 million (Q4 2025), $54.5 million (Q3 2025), and $43.9 million (Q2 2025).